News | July 18, 2021
Veeda Clinical Research acquires majority stake in Bioneeds
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The company will review FDA's response and decide on appropriate next steps soon.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Subscribe To Our Newsletter & Stay Updated
